Cite
MLA Citation
Yan Wang et al.. “A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome.” Journal of medical economics, vol. 23, 2021, pp. 1503–1515. http://access.bl.uk/ark:/81055/vdc_100124343056.0x000023